Given the vast number of medications that treat diabetes and obesity that keep popping up in the media today, it might be difficult to distinguish between their categories. Jardiance is one of the most widely used treatments for type 2 diabetes in the United States, but people always ask if it is the same as Ozempic, Wegovy, and Zepbound. The quick answer is that Jardiance is not a GLP-1 drug. But by knowing precisely why it is so, as well as comparing these two groups of drugs, you will be able to have a more knowledgeable discussion with your physician about your treatment plan.
Learn more about GLP-1 drugs and ways to reduce body weight here: glpweightloss.online.
What Is Jardiance?
The brand name of empagliflozin is Jardiance. This drug is a prescription drug manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company. The FDA approved Jardiance in August 2014, and it is totally dissimilar from GLP-1 medications because it belongs to a unique drug class, specifically the SGLT2 inhibitor category, which refers to the sodium-glucose cotransporter-2 inhibitors. Instead of mimicking any hormone in the body, Jardiance acts solely in the kidneys. Specifically, Jardiance inhibits the action of SGLT2, which reabsorbs about 90% of the glucose filtered in the kidney back to the bloodstream. However, upon the inhibition of this protein by Jardiance, the excess glucose will be flushed out of the body in the form of urine – carrying away both sugar and calories. Thus, Jardiance relies on the action of the kidneys rather than hormones produced by the gut. Jardiance neither induces insulin secretion nor affects appetite because it does not interfere with the central nervous system’s hunger signals. This prescription medicine is offered as a single daily dose tablet with a strength of either 10 mg or 25 mg, orally, and regardless of meal intake.
What Are GLP-1 Medications?
GLP-1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Zepbound, however, utilize a completely different principle of action. They simulate glucagon-like peptide-1, a gut hormone that your body produces in response to food intake to regulate blood glucose levels and promote satiety and gastrointestinal motility. This drug acts by activating GLP-1 receptors in multiple organs: the pancreas, intestines, and the brain. The effect of this is the glucose-dependent stimulation of insulin production, reduction in glucagon secretion, delayed stomach emptying, and considerable reduction of appetite. This, in turn, leads to much more significant weight loss compared to Jardiance. Most of the GLP-1 medications are administered via weekly injection, but there have been some notable improvements in oral pills over the past few years (especially in 2025 and 2026). The crucial difference here is that these are two different types of medication targeting the same medical issue via different mechanisms – hormones in the case of GLP-1 and filtration in the case of Jardiance.
Jardiance vs. GLP-1 Medications – Side-by-Side Comparison
| Feature | Jardiance (Empagliflozin) | GLP-1 Medications (e.g., Ozempic, Wegovy) |
| Drug Class | SGLT2 Inhibitor | GLP-1 Receptor Agonist (or Dual GIP/GLP-1) |
| Primary Mechanism | Blocks glucose reabsorption in the kidneys; eliminates sugar through urine. | Mimics gut hormones to boost insulin, slow digestion, and signal brain satiety. |
| Primary Use | Type 2 Diabetes (T2D), Heart Failure, and Chronic Kidney Disease (CKD). | T2D, Weight Management, Cardiovascular Risk, Sleep Apnea. |
| Weight Loss Effect | Modest (2–3% or ~5 lbs average). | Significant (15–22% of body weight with modern doses). |
| Form | Daily Oral Pill | Weekly Injection or Daily Pill (Wegovy Pill approved Dec 2025). |
| Heart Failure (HF) | First-line treatment for all types of HF (HFrEF and HFpEF). | Emerging 2026 data show benefits for HFpEF with obesity. |
| Stroke Prevention | Neutral effect on stroke risk. | Proven Reduction in non-fatal stroke risk (now in ACC/AHA guidelines). |
| Kidney Protection | Strongest data for slowing CKD progression. | Strong data (FLOW trial) specifically for Diabetic Kidney Disease. |
| Common Side Effects | UTIs, yeast infections, and dehydration. | Nausea, vomiting, “sulfur burps,” and constipation. |
What Is Jardiance Approved For?
Jardiance currently holds FDA approval for three distinct conditions:
Type 2 diabetes – as an adjuvant to diet and physical activity for the treatment of hyperglycemia in adults.
Cardiovascular risk reduction – to decrease the danger of mortality from cardiovascular issues in adult patients with type 2 diabetes and recognized cardiovascular illness. This was because of the groundbreaking EMPA-REG OUTCOME experiment, which demonstrated that Jardiance decreased mortality due to cardiovascular issues by 38 percent in contrast to placebo for at-risk individuals.
Heart failure – Jardiance is FDA-approved for the prevention of hospitalization and mortality from cardiovascular disease in adults with heart failure, whether or not they have type 2 diabetes. In the EMPEROR-Reduced study, Jardiance led to a 30 to 35 percent decrease in heart failure hospitalizations, which is an advantage that GLP-1 therapies have not yet been able to show.
Chronic kidney disease (CKD) – Jardiance is likewise indicated for preventing the development of kidney disease and cardiovascular death in adults with chronic kidney disease, regardless of their diabetic condition.
The FDA has not endorsed Jardiance for treating obesity. However, weight loss ranging from 2 to 3 kilograms is common when Jardiance causes glucosuria.
How Does Jardiance Compare to GLP-1 Drugs for Weight Loss?
This is one of the most frequent queries people ask when evaluating these two drugs – and the difference is substantial.GLP-1 drugs yield substantially more weight loss than does Jardiance. In trials, Wegovy (semaglutide) leads to about 15 percent weight loss, and Zepbound (tirzepatide) leads to 20 percent weight loss. On the other hand, Jardiance induces approximately 2 to 3 kilograms, which comes out to about 4 to 7 pounds, of weight loss resulting from the loss of calories via the urinary excretion of glucose. Jardiance-induced weight loss is a secondary phenomenon – not the main intention of the drug. GLP-1 drugs actively decrease appetite and cravings for food, making patients feel full, yielding the weight loss that Jardiance is not capable of delivering. If the aim is to lose weight in a medically effective way, then GLP-1 drugs are the correct discussion for having with a physician. However, if the patient is worried about the risk of heart disease or kidney health, along with diabetes, then perhaps Jardiance is actually the better medical option.
Where Jardiance Has a Clinical Advantage Over GLP-1s
Despite producing less weight loss, Jardiance has specific areas where the evidence is stronger than for GLP-1 medications:
Heart failure: Studies on SGLT2 inhibitors such as Jardiance have revealed an improvement in heart failure hospitalization by 30 to 35 percent across various large-scale studies – a trend observed among non-diabetic subjects. Currently, the American Diabetes Association suggests using SGLT2 inhibitors as first-line medication for individuals suffering from type 2 diabetes and heart failure. However, GLP-1 drugs have yet to provide similar benefits regarding heart failure.
Direct cardiovascular mortality reduction: The EMPA-REG study conducted on Jardiance revealed a reduction of cardiovascular mortality by 38 percent. Although GLP-1 drugs provide cardiovascular benefits, the results of Jardiance in managing heart failure and mortality rates in specific high-risk groups are particularly promising.
Kidney protection: Both categories of drugs are known to be renal protective; however, SGLT2 inhibitors have provided favorable outcomes among non-diabetics suffering from chronic kidney disease (CKD), marking a widespread application that revolutionized CKD management practices.
During a discussion at the American Pharmacists Association Annual Meeting in 2025, the pharmacology specialists stated it accurately: GLP-1 drugs are better in preventing strokes, causing weight loss, and controlling glucose levels, whereas SGLT2 inhibitors, including Jardiance, are superior in treating heart failures, lowering cardiovascular mortality, and renal protection.
Can You Take Jardiance and a GLP-1 Together?
Absolutely – and this pairing is clinically well-established. The reason is that the mechanisms of action for Jardiance and GLP-1 drugs are entirely distinct, thus synergizing rather than overlapping. Indeed, many type 2 diabetics who suffer from several disorders at once, such as those who need substantial weight loss along with having some heart or renal disease predispositions, might receive a prescription for both medications. Studies have demonstrated a synergistic effect of this pairing regarding the control of blood glucose levels, weight loss, and cardioprotection. However, when prescribing both Jardiance and GLP-1 drugs, clinicians should pay attention to issues of potential dehydration, gastrointestinal complications, as well as proper dose titration of insulin and sulfonylureas to prevent hypoglycemia.
Side Effects – What’s Different Between Jardiance and GLP-1 Drugs
The side effects of these drugs are rather different, which could impact which drug would be suitable for a particular patient.
The most frequent adverse reactions of Jardiance are associated with its mechanism of action and involve urinary tract infection and genital mycotic infection due to an increased concentration of glucose in the urine and its creation of favorable conditions for bacterial and fungal flora. Dehydration and hypotension could also arise. A very rare complication is diabetic ketoacidosis that can appear in individuals without elevated blood glucose concentrations. As for the side effects of GLP-1 agonists, they mostly affect the digestive system: nausea, vomiting, diarrhea, and constipation. They usually become milder after the dosage is adjusted. Individuals who have trouble dealing with recurrent UTIs and yeast infections can experience more comfortable use of GLP-1 drugs. On the other hand, patients who find it challenging to cope with gastrointestinal complications of GLP-1 drugs will find the side effects of Jardiance more tolerable.
For further inquiries regarding which drug suits you best, visit glpweightloss.online or your healthcare professional.
Frequently Asked Questions
Is Jardiance a GLP-1 medication?
No. Jardiance is an SGLT2 inhibitor, whereas GLP-1 is an agonist of GLP-1 receptors. While Jardiance functions by inhibiting the reabsorption of glucose in the kidneys so that excess glucose is excreted via urine, GLP-1 drugs act by imitating a hormone secreted in the gut that helps regulate insulin and digestive processes. These two types of drugs differ greatly in their mode of action, uses, and side effects.
Does Jardiance cause weight loss like GLP-1 drugs?
Not at all. The weight loss caused by taking Jardiance is moderate: the patient can lose about 2-3 kg due to the elimination of glucose from the body via urine. In comparison, GLP-1 drugs cause significant weight loss – from 15 to 22 percent. GLP-1 drugs cause weight loss, actively reducing hunger and appetite.
What is Jardiance best used for?
Jardiance is extremely effective for those diabetic patients who suffer from heart failure, established cardiovascular diseases, or chronic renal impairment. It has proven to decrease the risk of heart failure hospitalizations by 30 to 35 percent, as well as the risk of cardiovascular mortality by 38 percent.
Can I take Jardiance and a GLP-1 medication at the same time?
Absolutely! It’s a common practice to combine these medications, and there are clinical benefits from doing so since the two drugs have totally separate mechanisms and, thus, can complement one another. Your healthcare professional will watch out for signs of dehydration and adjust other antidiabetic medication dosage as necessary.
Is Jardiance better or worse than Ozempic?
There is no universal best choice among these two medications because their clinical applications are quite different. Ozempic is better than Jardiance when it comes to losing extra weight, reducing food intake, and lowering blood glucose levels. Jardiance is better for managing heart failure and is equally or more effective regarding some other cardiovascular and renal outcomes. Everything depends on individual circumstances.
Does Jardiance require an injection like GLP-1 medications?
Absolutely not. Jardiance is an oral drug taken once per day. That is one of its major pluses because no injections are needed. There are new oral GLP-1 drugs on the market, like the recently approved in December 2025 Wegovy; however, the majority of the existing GLP-1 agonists remain injectable weekly treatments.
Resources
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
https://www.ncbi.nlm.nih.gov/books/NBK576405/
https://www.healthline.com/health/drugs/jardiance
https://www.medicalnewstoday.com/articles/drugs-jardiance
https://www.everlywell.com/blog/weight-management/jardiance-vs-ozempic/
https://www.tryeden.com/post/is-jardiance-a-glp1
https://pmc.ncbi.nlm.nih.gov/articles/PMC10172076/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12383900/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11898315/
https://www.goodrx.com/jardiance/weight-loss
https://pmc.ncbi.nlm.nih.gov/articles/PMC8099977/
https://www.webmd.com/drugs/jardiance-empagliflozin
https://iapam.com/medical-weight-management-library/a-comparison-of-ozempic-and-jardiance
https://medlibrary.org/lib/rx/meds/jardiance-1/
